Neurotoxic vulnerability underlying schizophrenia spectrum disorders

Handbook of Neurotoxicity

Volumn 3, Issue , 2014, Pages 2181-2205

  Archer, Trevor ^a   Karilampi, Ulla ^a   Ricci, Serafino ^b   Rapp Ricciardi, Max ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

GFK; Imaging; Infection; MAM; Perinatal; Reelin; Trophic factors; Vulnerability

Indexed keywords

EID: 84940823537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5836-4_119     Document Type: Chapter

References (214)

1. Adell, A., Jimenez-Sanchez, L., Lopez-Gil, X., & Romon, T. (2012). Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophrenia Bulletin, 38, 9-14.
2. Akil, M., & Lewis, D. A. (1997). Cytoarchitecture of the entorhinal cortex in schizophrenia. The American Journal of Psychiatry, 154, 1010-1012.
3. Alexander-Bloch, A. F., Gogtay, N., Meunier, D., Birn, R., Clasen, L., Lalonde, F., Lenroot, R., Giedd, J., & Bullmore, E. T. (2010). Disrupted modularity and local connectivity of brain functional networks in childhood-onset schizophrenia. Frontiers in Systems Neuroscience, 4, 147.
4. Altar, C. A., Cai, N., Bliven, T., Juhasz, M., Conner, J. M., Acheson, A. L., Lindsay, R. M., & Wiegand, S. J. (1997). Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature, 389, 856-860.
5. Aoyama, N., Theberge, J., Drost, D. J., Manchanda, R., Northcott, S., Neufeld, R. W., Menon, R. S., Rajakumar, N., Pavlosky, W. F., Densmore, M., Schaefer, B., & Williamson, P. C. (2011). Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. The British Journal of Psychiatry, 198, 448-456.
6. Archer, T. (2010). Neurodegeneration in schizophrenia. Expert Review of Neuro therapeutics, 10, 1131-1141.
7. Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T. (2010a). Staging perspectives in neurodevelopmental aspects of neuropsychiatry: Agents, phases and ages at expression. Neurotoxicity Research, 18, 287-305.
8. Archer, T., Kostrzewa, R. M., Palomo, T., & Beninger, R. J. (2010b). Clinical staging in the pathophysiology of psychotic and affective disorders: Facilitation of prognosis and treatment. Neurotoxicity Research, 18, 211-228.
9. Arias, I., Sorlozano, A., Villegas, E., de Dios, L. J., McKenney, K., Cervilla, J., Gutierrez, B., & Gutierrez, J. (2012). Infectious agents associated with schizophrenia: A meta-analysis. Schizophrenia Research, 136(1-3), 128-136.
10. Arnold, S. E., Hyman, B. T., Van Hoesen, G. W., & Damasio, A. R. (1991). Some cytoarchi- tectural abnormalities of the entorhinal cortex in schizophrenia. Archives of General Psychiatry, 48, 625-632.
11. Arnold, S. E., Ruscheinsky, D. D., & Han, L. Y. (1997). Further evidence of abnormal cytoarch- itecture of the entorhinal cortex in schizophrenia using spatial point pattern analysis. Biological Psychiatry, 42, 639-647.
12. Avila, J., Lucas, J. J., Perez, M., & Hernandez, F. (2004). Role of tau protein in both physiological and pathological conditions. Physiological Reviews, 84, 361-384.
13. Baiano, M., Perlini, C., Rambaldelli, G., Cerini, R., Dusi, N., Bellani, M., Spezzapria, G., Versace, A., Balestrieri, M., Mucelli, R. P., Tansella, M., & Brambilla, P. (2008). Decreased entorhinal cortex volumes in schizophrenia. Schizophrenia Research, 102, 171-180.
14. Balduini, W., Lombardelli, G., Peruzzi, G., & Cattabeni, F. (1991). Treatment with methylazox- ymethanol at different gestational days: Physical, reflex development and spontaneous activity in the offspring. Neurotoxicology, 12, 179-188.
15. Ballatori, N., Krance, S. M., Notenboom, S., Shi, S., Tieu, K., & Hammond, C. L. (2009). Glutathione dysregulation and the etiology and progression of human diseases. Biological Chemistry, 390, 191-214.
16. Bartzokis, G. (2011). Neuroglialpharmacology: White matter pathophysiologies and psychiatric treatments. Frontiers in Bioscience, 17, 2695-2733.
17. Bayer, S. A., & Altman, J. (2004). Development of the telencephalon: Neural stem cells, neurogenesis, and neuronal migration. In G. Paxinos (Ed.), The rat neural system (pp. 27-73). San Diego: Elsevier.
18. Benros, M. E., Nielsen, P. R., Nordentoft, M., Eaton, W. W., Dalton, S. O., & Mortensen, P. B. (2011). Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. The American Journal of Psychiatry, 168, 1303-1310.
19. Berger, Z., Ttofi, E. K., Michel, C. H., Pasco, M. Y., Tenant, S., Rubinsztein, D. C., & O'Kane, C. J. (2005). Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Human Molecular Genetics, 14, 3003-3011.
20. Bergman, O., Westberg, L., Lichtenstein, P., Eriksson, E., & Larsson, H. (2011). Study on the possible association of brain-derived neurotrophic factor polymorphism with the developmental course of symptoms of attention deficit and hyperactivity. The International Journal of Neuropsychopharmacology, 14, 1367-1376.
21. Bleich, S., Frieling, H., & Hillemacher, T. (2007). Elevated prenatal homocysteine levels and the risk of schizophrenia. Archives of General Psychiatry, 64, 980-981.
22. Bleich, S., Junemann, A., Von Ahsen, N., Lausen, B., Ritter, K., Beck, G., Naumann, G. O., & Kamhuber, J. (2002). Homocysteine and risk of open-angle glaucoma. Journal of Neural Transmission, 109, 1499-1504.
23. Bosia, M., Buonocure, M., Guglielmino, C., Pirovana, A., Lorenzi, C., Marcone, A., Bramanti, P., Cappa, S. F., Aquglia, E., Smerladi, E., & Cavallaro, R. (2011). Saitohin polymorphism and executive dysfunction in schizophrenia. Neurological Sciences, 33(5), 1051-1056. doi:10.1007/s10072-0893-9.
24. Brambrink, A. M., Evers, A. S., Avidan, M. S., Farber, N. B., Smith, D. J., Martin, L. D., Dissen, G. A., Creeley, C. E., & Olney, J. W. (2012). Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain. Anesthesiology, 116(2), 372-384.
25. Brown, A. M., & Ransom, B. R. (2007). Astrocyte glycogen and brain energy metabolism. Glia, 55, 1263-1271.
26. Brown, A. M., Baltan Tekkok, S., & Ransom, B. R. (2003). Glycogen regulation and functional role in mouse white matter. The Journal of Physiology, 549, 501-512.
27. Brown, A. M., Baltan Tekkok, S., & Ransom, B. R. (2004). Energy transfer from astrocytes to axons: The role of CNS glycogen. Neurochemistry International, 45, 529-536.
28. Brown, A. S. (2011). Exposure to prenatal infection and risk of schizophrenia. Frontiers in Psychiatry, 2, 63.
29. Brown, A. S. (2012). Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Developmental Neurobiology, 72(10), 1272-1276. doi:10.1002/dneu.22024.
30. Brown, A. S., & Derkits, E. J. (2010). Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. The American Journal of Psychiatry, 167, 261-280.
31. Brown, A. S., & Patterson, P. H. (2011). Maternal infection and schizophrenia: Implications for prevention. Schizophrenia Bulletin, 37, 284-290.
32. Brown, A. S., Bottiglieri, T., Schaefer, C. A., Quesenberry, C. P. J. R., Liu, L., Bresnahan, M., & Susser, E. S. (2007). Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Archives of General Psychiatry, 64, 980-981.
33. Brown, A. S., & Susser, E. S. (2005). Homocysteine and schizophrenia: From prenatal to adult life. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 29, 1175-1180.
34. Brown, A. S., & Susser, E. S. (2008). Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophrenia Bulletin, 34, 1054-1063.
35. Brown, A. S., Vinogradov, S., Kremen, W. S., Poole, J. H., Deicken, R. F., Penner, J. D., McKeague, I. W., Kochetkova, A., Kern, D., & Schaefer, C. A. (2009). Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. The American Journal of Psychiatry, 166, 683-690.
36. Brown, A. S., Vinogradov, S., Kremen, W. S., Poole, J. H., Bao, Y., Kern, D., & McKeague, I. W. (2011). Association of maternal genital and reproductive infections with verbal memory and motor deficits in adult schizophrenia. Psychiatry Research, 188, 179-186.
37. Buckley, P. F., Pillai, A., Evans, D., Stirewalt, E., & Mahadik, S. (2007). Brain-derived neurotrophic factor in first-episode psychosis. Schizophrenia Research, 91, 1-5.
38. Buckley, P. F., Pillai, A., & Howell, K. R. (2011). Brain-derived neurotrophic factor: Findings in schizophrenia. Current Opinion in Psychiatry, 24(2), 122-127.
39. Burd, I., Balakrishnan, B., & Kannan, S. (2012). Models of fetal brain injury, intrauterine inflammation, and preterm birth. American Journal of Reproductive Immunology, 67, 287-294. doi:10.1111/j.1600-0897.2012.01110.x.
40. Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010). 1H-MRS at 4 tesla in minimally treated early schizophrenia. Molecular Psychiatry, 15, 629-636.
41. Cannon, M., Caspi, A., & Moffitt, T. E. (2002a). Evidence for early, specific, pandevelopment impairment in schizophreniform disorder: Results from a longitudinal birth cohort. Archives of General Psychiatry, 59, 449-456.
42. Cannon, M., Murray, R. M., & Jones, P. (2002b). Obstetric complications and schizophrenia: Past, present and future. The American Journal of Psychiatry, 159, 1080-1092.
43. Carluccio, M. A., Ancora, M. A., Massaro, M., Carluccio, M., Scoditti, E., Distante, A., Storelli, C., & De Caterina, R. (2007). Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: Protective role of Mediterranean diet polyphenolic antioxidants. American Journal of Physiology. Heart and Circulatory Physiology, 293, H2344-H2354.
44. Cattabeni, F., & Di Luca, M. (1997). Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiological Reviews, 77, 199-215.
45. Ceranik, K., Deng, J., Heimrich, B., Lubke, J., Zhao, S., Förster, E., & Frotscher, M. (1999). Hippocampal Cajal-Retzius cells project to the entorhinal cortex: Retrograde tracing and intracellular tracing studies. The European Journal of Neuroscience, 11, 4278-4290.
46. Chan, M. H., Chiu, P. H., Lin, C. Y., & Chen, H. H. (2012). Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine. Schizophrenia Research, 136, 96-103.
47. Chen, C. C., & Huang, T. L. (2011). Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Research, 189, 327-330.
48. Chen, S., & Hillman, D. E. (1986). Selective ablation of neurons by methylazoxymethanol during pre- and postnatal brain development. Experimental Neurology, 94, 103-119.
49. Ciani, E., Frenquelli, M., & Contestabile, A. (2003). Developmental expression of the cell cycle and apoptosis controlling gene, Lotl, in the rat cerebellum and in cerebellar granule cells. Brain Research. Developmental Brain Research, 142, 193-202.
50. Combarros, O., Rodero, L., Infante, J., Palacio, E., Llorca, J., Fernandez-Viadero, C., Peha, N., & Berciano, J. (2003). Age-dependent association between the Q7R polymorphism in the Saitohin gene and sporadic Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 16, 132-135.
51. Correll, C. U., & Schenk, E. M. (2008). Tardive dyskinesias and new antipsychotics. Current Opinion in Psychiatry, 21, 151-156.
52. Dauvermann, M. R., Mukherjee, P., Moorhead, W. T., Stanfield, A. C., Fusar-Poli, P., Lawrie, S. M., & Whalley, H. C. (2012). Relationship between gyrification and functional connectivity of the prefrontal cortex in subjects at high genetic risk of schizophrenia. Current Pharmaceutical Design, 18(4), 434-442. PMID: 22239574.
53. Dean, O. M., van den Buuse, M., Berk, M., Copolov, D. L., Mavros, C., & Bush, A. I. (2011). N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and D-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. Neuroscience Letters, 499, 149-153.
54. Dietrich-Muszalska, A., & Kontek, B. (2010). Lipid peroxidation in patients with schizophrenia. Psychiatry and Clinical Neuroscience, 64, 469-475.
55. Dietrich-Muszalska, A., & Olas, B. (2007). Isoprostanes as indicators of oxidative stress in schizophrenia. The World Journal of Biological Psychiatry, 14, 1-6.
56. Dietrich-Muszalska, A., Olas, B., & Rabe-Jablonska, J. (2005). Oxidative stress in blood platelets from schizophrenic patients. Platelets, 16, 386-391.
57. Dietrich-Muszalska, A., Olas, B., Glowacki, R., & Bald, E. (2009). Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology, 59, 1-7.
58. Dietrich-Muszalska, A., Malinowska, J., Olas, B., Glowacki, R., Bald, E., Wachowicz, B., & Rabe-Jablonska, J. (2012). The oxidative stress may be induced by the elevated homocysteine in schizophrenia patients. Neurochemical Research, 37, 1057-1062.
59. Do, K. Q., Cabungal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009). Redox dysregulation, neurodevelopment and schizophrenia. Current Opinion in Neurobiology, 19, 220-230.
60. Dringen, R., & Hirrlinger, J. (2003). Glutathione pathways in the brain. Biological Chemistry, 384, 505-516.
61. Dringen, K. O., Loschmann, P. A., & Hamprecht, B. (1997). Use of dipeptides for the synthesis of glutathione by astroglia-rich primary cultures. Journal of Neurochemistry, 69, 868-874.
62. Ducharme, G., Lowe, G. C., Goutagny, R., & Williams, S. (2012). Early alterations in hippocampal circuitry and theta rhythm generation in a mouse model of prenatal infection: Implications for schizophrenia. PloS One, 7(1), e29754.
63. Eastwood, S. L., & Harrison, P. J. (2006). Cellular basis of reduced cortical reelin expression in schizophrenia. The American Journal of Psychiatry, 163, 540-542.
64. Egerton, A., & Stone, J. M. (2012). The glutamate hypothesis of schizophrenia: Neuroimaging and drug development. Current Pharmaceutical Biotechnology, 13(8), 1500-1512.
65. Elia, J., Laracy, S., Allen, J., Nissley-Tsiopinis, J., & Borgmann-Winter, K. (2011). Epigenetics: Genetics versus life experiences. Current Topics in Behavioral Neuroscience, 9, 317-340.
66. Ellenbroek, B. A., van den Kroonenberg, P. T., & Cools, A. R. (1998). The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophrenia Research, 30, 251-260.
67. Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M., & Gogos, J. A. (2004). Convergent evidence for impaired AKT1-GSK3 signaling in schizophrenia. Nature Genetics, 36, 131-137.
68. Falkai, P., Kovalenko, S., Schneider-Axmann, T., Ovary, I., & Honer, W. G. (2003). Second replication of disturbed pre-alpha-cell migration in the entorhinal cortex of schizophrenic patients. Schizophrenia Research, 60, 71-74.
69. Fatemi, S. H., Earle, J. A., & McMenomy, T. (2000). Reduction in reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Molecular Psychiatry, 5, 654-663.
70. Favalli, G., Li, J., Belmonte-de-Abreu, P., Wong, A. H., & Daskalakis, Z. J. (2012). The role of BDNF in the pathophysiology and treatment of schizophrenia. Journal of Psychiatric Research, 46, 1-11.
71. Featherstone, R. E., Rizos, Z., Nobrega, J. N., Kapur, S., & Fletcher, P. J. (2007). Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: Parallels to schizophrenia. Neuropsychopharmacology, 32, 483-492.
72. Ferguson, S. A., Paule, M. G., & Holson, R. R. (1996). Functional effects of methylazoxy- methanol-induced cerebellar hypoplasia in rats. Neurotoxicology and Teratology, 18, 529-537.
73. Ferguson, S. A., & Holson, R. R. (1997). Methylazoxymethanol-induced micrencephaly in the brown Norway strain: Behavior and brain weight. International Journal of Developmental Neuroscience, 15, 75-86.
74. Ferrer, I., Pozas, E., Marti, M., Blanco, R., & Planas, A. M. (1997). Methylazoxymethanol- induced apoptosis in the external granule cell layer of the developing cerebellum of the rat is associated with strong c-jun expression and formation of high molecular weight c-jun complexes. Journal of Neuropathology and Experimental Neurology, 56, 1-9.
75. Fiore, M., Korf, J., Antonelli, A., Talamini, L., & Aloe, L. (2002). Long-lasting effects of prenatal MAM treatment on water maze performance in rats: Associations with altered brain development and neurotrophin levels. Neurotoxicology and Teratology, 24, 179-191.
76. Fitzgerald, P. J. (2012). The NMDA receptor may participate in widespread suppression of circuit level neural activity, in addition to a similarly prominent role in circuit level activation. Behavioural Brain Research, 230, 291-298.
77. Flagstad, P., Glenthoj, B. Y., & Didriksen, M. (2005). Cognitive deficits caused by late gestational disruption of neurogenesis in rats: A preclinical model of schizophrenia. Neuropsychopharmacology, 30, 250-260.
78. Fontes, M. A., Bolla, K. I., Cunha, P. J., Almeida, P. P., Jungerman, F., Laranjeira, R. R., Bressan, R. A., & Lacerda, A. L. (2011). Cannabis use before age 15 and subsequent executive functioning. The British Journal of Psychiatry, 198, 442-447.
79. Furukawa, T., Mizukawa, R., Hirai, T., Fujihara, S., Kitamura, T., & Takahashi, K. (1998). Childhood parental loss and schizophrenia: Evidence against pathogens but for some pathoplastic effects. Psychiatry Research, 81, 353-362.
80. Gao, L., Tse, S. W., Conrad, C., & Andreadis, A. (2005). Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6. The Journal of Biological Chemistry, 280, 39268-39272.
81. Geddes, J. R., Verdoux, H., & Takei, N. (1999). Schizophrenia and complications of pregnancy and labour: An individual patient data meta-analysis. Schizophrenia Bulletin, 25, 413-423.
82. Gibbs, M. E., Anderson, D. G., & Hertz, L. (2006). Inhibition of glycogenolysis in astrocytes interrupts memory consolidation in young chickens. Glia, 54, 214-222.
83. Gill, K. M., Lodge, D. J., Cook, J. M., Aras, S., & Grace, A. A. (2011). A novel a5GABAAR- postive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology, 36, 1903-1911.
84. Goldman, A. L., Pezawas, L., Mattay, V. S., Fischl, B., Verchinski, B. A., Chen, Q., Weinberger, D. R., & Meyer-Lindenberg, A. (2009). Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Archives of General Psychiatry, 66, 467-477.
85. Gomez-Sintes, R., Hernandez, F., Lucas, J. J., & Avila, J. (2011). GSK-3 mouse models to study neuronal apoptosis and neurodegeneration. Frontiers in Molecular Neuroscience, 4, 1-11. doi:103389/fnmol.2011.00045.
86. Goto, Y., & Grace, A. A. (2006). Alterations in medial prefrontal cortical activity and plasticity in rats with disruption of cortical development. Biological Psychiatry, 60, 1259-1267.
87. Goto, N., Yoshimura, R., Kakeda, S., Moriya, J., Hayashi, K., Ikenouchi-Sugita, A., Umene- Nakano, W., Hori, H., Ueda, N., Korogi, Y., & Nakamura, J. (2010). Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls. European Psychiatry, 26, 57-63.
88. Gourevitch, R., Rocher, C., Le Pen, G., Krebs, M. O., & Jay, T. M. (2004). Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behavioural Pharmacology, 15, 287-292.
89. Graff, J., Dohoon, K., Dobbin, M. M., & Tsai, L. H. (2011). Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiological Reviews, 91, 603-649.
90. Gratacos, M., Gonzalez, J. R., Mercader, J. M., de Cid, R., Urretavizcaya, M., & Estivill, X. (2007). Brain-derived neurotrophic factor Val66Met and psychiatric disorders: Meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders and schizophrenia. Biological Psychiatry, 61, 911-922.
91. Grillo, R. W., Ottoni, G. L., Leke, R., Souza, D. O., Portela, L. V., & Lara, D. R. (2007). Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. Journal of Psychiatric Research, 41, 31-35.
92. Guidotti, A., Auta, J., Davis, J. M., Di-Giorgi-Gerevini, V., Dwivedi, Y., Grayson, D. R., Impagnatiello, F., Pandey, G., Pesold, C., Sharma, R., Uzunov, D., & Costa, E. (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Archives of General Psychiatry, 57, 1061-1069.
93. Harrison, P. J. (2004). The hippocampus in schizophrenia: A review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology, 174, 151-162.
94. Hertz, L., O'Dowd, B. S., Ng, K. T., & Gibbs, M. E. (2003). Reciprocal changes in forebrain contents of glycogen and glutamate/glutamate during early memory consolidation in the day- old chick. Brain Research, 994, 226-233.
95. Hoenicka, J., Garrido, E., Martinez, I., Ponce, G., Aragties, M., Rodriguez-Jimenez, R., Espaha- Serrano, L., Alvira-Botero, X., Santos, J. L., Rubio, G., Jimenez-Arriero, M. A., Palomo, T., & PARGPARG. (2010). Gender-specific COMT Val158Met polymorphism association in Spanish schizophrenic patients. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 153B, 79-85.
96. Honea, R. A., Meyer-Lindenberg, A., Hobbs, K. B., Pezawas, L., Mattay, V. S., Egan, M. F., Verchinski, B., Passingham, R. E., Weinberger, D. R., & Callicott, J. H. (2008). Is grey matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometric study of patients with schizophrenia and their healthy siblings. Biological Psychiatry, 63, 465-474.
97. Hradetzky, S., Sanderson, T. M., Tsang, T. M., Sherwood, J. L., Fitzjohn, S. M., Lakics, V., Malik, N., Schoeffmann, S., O'Neill, M. J., Cheng, T. M., Harris, L. W., Rahmoune, H., Guest, P. C., Sher, E., Collingridge, G. L., Holmes, E., Tricklebank, M. D., & Bahn, S. (2011). The methylazoxymethanol acetate (MAM-E17) rat model: Molecular and functional effects in the hippocampus. Neuropsychopharmacology, 37, 364-377.
98. Hyman, C., Hofer, M., Barde, Y. A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991). BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 350, 230-232.
99. Ikeda, Y., Yahata, N., Ito, I., Nagano, M., Toyota, T., Yoshikawa, T., Okubo, Y., & Suzuki, H. (2008). Low serum levels of brain derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophrenia Research, 101, 58-66.
100. Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., Pappas, G. D., Tueting, P., Sharma, R. P., & Costa, E. (1998). A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 95, 15718-15723.
101. Jablonka, E., & Raz, G. (2009). Transgenerational epigenetic inheritance: Prevalence, mechanisms, and implications for the study of heredity and evolution. The Quarterly Review of Biology, 84, 131-176.
102. Jacob, C. P., Nguyen, T. T., Dempfle, A., Heine, M., Windemuth-Kieselbach, C., Baumann, K., Jacob, F., Prechtl, J., Wittlich, M., Herrmann, M. J., Gross-Lesch, S., Lesch, K. P., & Reif, A. (2010). A gene-environment investigation on personality traits in two independent clinical sets of adult patients with personality disorder and attention deficit/hyperactivity disorder. European Archives Psychiatry and Clinical Neuroscience, 260, 317-326.
103. Jafari, S., Fernandez-Enright, F., & Huang, X. F. (2012). Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. Journal of Neurochemistry, 120, 371-384.
104. Jankovic, N., Kecmanovic, M., Dimitrijevic, R., Keckarevic Markovic, M., Dobricic, V., Keckarevic, D., Savic Pavicevic, D., & Romac, S. (2008). HD phenocopies - Possible role of Saitohin gene. The Journal of Neuroscience, 118, 391-397.
105. Jaworski, T., Dewachter, I., Lechat, B., Gees, M., Kremer, A., Demedts, D., Borghgraef, P., Devijver, H., Kügler, S., Patel, S., Woodgett, J. R., & Van Leuven, F. (2011). GSK-3a/ß kinases and amyloid production in vivo. Nature, 480(7376), E4-E5.
106. Jonsson, S. A., Luts, A., Guldberg-Kjaer, N., & Ohman, R. (1999). Pyramidal neuron size in the hippocampus of schizophrenics correlates with total cell count and degree of cell disarray. European Archives of Psychiatry and Clinical Neuroscience, 249, 169-173.
107. Kaidanovich-Beilin, O., & Woodgett, J. R. (2011). GSK-3: Functional insights from cell biology and animal models. Frontiers in Molecular Neuroscience, 4, 40.
108. Karilampi, U., Helldin, L., Hjarthag, F., Norlander, T., & Archer, T. (2007). Verbal learning in schizopsychotic outpatients and healthy volunteers as a function of cognitive performance levels. Archives of Clinical Neuropsychology, 22, 161-174.
109. Karilampi, U., Helldin, L., & Archer, T. (2011). Cognition and global assessment of functioning in male and female outpatients with schizophrenia spectrum. The Journal of Nervous and Mental Disease, 199, 445-448.
110. Kneeland, R. E., & Fatemi, S. H. (2012). Viral infection inflammation and schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 42, 35-48. PMID: 22349576.
111. Konradi, C., Yang, C. K., Zimmerman, E. I., Lohmann, K. M., Gresch, P., Pantazopoulos, H., Berretta, S., & Heckers, S. (2011). Hippocampal interneurons are abnormal in schizophrenia. Schizophrenia Research, 131, 165-173.
112. Lafarga, M., Lerga, A., Andres, M. A., Polanco, J. L., Calle, E., & Berciano, M. T. (1997). Apoptosis induced by methylazoxymethanol in developing rat cerebellum: Organization of the cell nucleus and its relationship to DNA and tRNA degradation. Cell and Tissue Research, 289, 25-38.
113. Lahti, A. C., Weiler, M. A., Holcomb, H. H., Tamminga, C. A., Carpenter, W. T., & McMahon, R. (2006). Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology, 31, 221-230.
114. Large, C. H., Bison, S., Sartori, I., Read, K. D., Gozzi, A., Quarta, D., Antolini, M., Hollands, E., Gill, C. H., Gunthorpe, M. J., Idris, N., Neill, J. C., & Alvaro, G. S. (2011). The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: Potential for novel treatments for schizophrenia. The Journal of Pharmacology and Experimental Therapeutics, 338, 100-113.
115. Lavoie, S., Allaman, I., Petit, J. M., Do, K. Q., & Magistretti, P. J. (2011). Altered glycogen metabolism in cultured astrocytes from mice with chronic glutathione deficit: Relevance for neuroenergetics in schizophrenia. PloS One, 6, e22875.
116. Le Pen, G., Jay, T. M., & Krebs, M. O. (2011). Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. Journal of Psychopharmacology, 25, 822-835.
117. Lee, M. H., & Rabe, A. (1992). Premature decline in Morris water maze performance of aging microencephalic rats. Neurotoxicology and Teratology, 14, 383-392.
118. Lee, A. H., Lange, C., Ricken, R., Hellweg, R., & Lang, U. E. (2011). Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. Journal of Clinical Psychopharmacology, 31, 334-336.
119. Leng, A., Jongen-Relo, A. L., Pothuizen, H. H., & Feldon, J. (2005). Effects of prenatal methylazoxymethanol acetate (MAM) treatment in rats on water maze performance. Behavioural Brain Research, 161, 291-298.
120. Li, H. C., Chen, Q. Z., Ma, Y., & Zhou, J. F. (2006). Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study. Journal of Zhejiang University Science B, 12, 981-986.
121. Lillrank, S. M., Lipska, B. K., Kolachana, B. S., & Weinberger, D. R. (1999). Attenuated extracellular dopamine levels after stress and amphetamine in the nucleus accumbens of rats with neonatal ventral hippocampal damage. Journal of Neural Transmission, 106, 183-196.
122. Lipska, B. K., & Weinberger, D. R. (1994). Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology, 10, 199-205.
123. Lipska, B. K., Jaskiw, G. E., Chrapusta, S., Karoum, F., & Weinberger, D. R. (1992). Ibotenic acid lesions of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Research, 585, 1-6.
124. Lipska, B. K., Swerdlow, N. R., Geyer, M. A., Jaskiw, G. E., Braff, D. L., & Weinberger, D. R. (1995). Neonatal excitotoxic lesions hippocampal damage in rats causes post pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology, 122, 35-43.
125. Lipska, B. K., Kolb, B., Halim, N., & Weinberger, D. R. (2001). Synaptic abnormalities in prefrontal cortex and nucleus accumbens of adult rats with neonatal hippocampal damage. Schizophrenia Research, 49, 47-51.
126. Lodge, D. J., & Grace, A. A. (2008). Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotoxicity Research, 14, 97-104.
127. Lodge, D. J., Behrens, M. M., & Grace, A. A. (2009). A loss of parvalbumin-containing interneurons is associated with loss of oscillatory activity in an animal model of schizophrenia. The Journal of Neuroscience, 29, 2344-2354.
128. Lodge, D. J., & Grace, A. A. (2012). Gestational methylazoxymethanol acetate administration alters proteomic and metabolomics markers of hippocampal glutamatergic transmission. Neuropsychopharmacology, 37, 319-320.
129. Lorenzi, C., Marcone, A., Pirovano, A., Marino, E., Cordici, F., Cerami, C., Delmonte, D., Cappa, S. F., Bramanti, P., & Smeraldi, E. (2010). Serotonin transporter and saitohin genes in risk of Alzheimer's disease and frontotemporal lobar dementia: Preliminary findings. Neurological Science, 31, 741-749.
130. Macedo, D. S., Araujo, D. P., Sampaio, L. R., Vasconcelos, S. M., Sales, P. M., Sousa, F. C., Hallak, J. E., Crippa, J. A., & Carvalho, A. F. (2012). Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: A systematic review. Brazilian Journal of Medical and Biological Research, 45, 179-186.
131. Maloku, E., Covelo, I. R., Hanbauer, I., Guidotti, A., Kadriu, B., Hu, Q., Davis, J. M., & Costa, E. (2010). Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression. Proceedings of the National Academy of Sciences of the United States of America, 107, 4407-4411.
132. Marona-Lewicka, D., Nichols, C. D., & Nichols, D. E. (2011). An animal model of schizophrenia based on chronic LSD administration: Old idea, new results. Neuropharmacology, 61, 503-512.
133. Matricon, J., Bellon, A., Frieling, H., Kebir, O., Le Pen, G., Beuvon, F., Daumas-Dupont, C., Jay, T. M., & Krebs, M.-O. (2010). Neuropathological and reelin deficiencies in the hippocampal formation of rats exposed to MAM: Differences and similarities with schizophrenia. PloS One, 5, e1029.
134. Meyer, U. (2011). Developmental neuroinflammation and schizophrenia. Progress in NeuroPsychopharmacology & Biological Psychiatry, 42, 20-34. PMID: 22122877.
135. Meyer-Lindenberg, A. (2011). Neuroimaging and the question of neurodegeneration in schizophrenia. Progress in Neurobiology, 95, 514-516.
136. Meyer-Lindenberg, A., Olsen, R. K., Kohn, P. D., Brown, T., Egan, M. F., Weinberger, D. R., & Berman, K. F. (2005). Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Archives of General Psychiatry, 62, 379-386.
137. Miller, J., Williamson, P., Jensen, J. E., Manchanda, R., Menon, R., Neufeld, R., Rajakumar, N., Pavlosky, W., Densmore, M., Schaefer, B., & Drost, D. J. (2009). Longitudinal 4.0 Testa (31)P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia. Psychiatry Research Neuroimaging, 173, 155-157.
138. Miller, R., & Chouinard, G. (1993). Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry, 34, 713-738.
139. Miyata, T., Ono, Y., Okamoto, M., Masaoka, M., Sakakibara, A., Kawaguchi, A., Hashimoto, M., & Ogawa, M. (2010). Migration, early axonogenesis, and reelin-dependent layer-forming behavior of early/posterior-born Purkinje cells in the developing mouse lateral cerebellum. Neural Development, 5, 23.
140. Mohammed, A. K., Jonsson, G., Söderberg, U., & Archer, T. (1986a). Impaired selective attention in methylazoxymethanol-induced microencephalic rats. Pharmacology Biochemistry and Behavior, 24, 975-981.
141. Mohammed, A. K., Jonsson, G., Sundström, E., Minor, B. G., Söderberg, U., & Archer, T. (1986b). Selective attention and place navigation in rats treated prenatally with methylazoxymethanol. Brain Research. Developmental Brain Research, 30, 145-155.
142. Moore, H., Jentsch, J. D., Ghajarnia, M., Geyer, M. A., & Grace, A. A. (2006). A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: Implications for the neuropathology of schizophrenia. Biological Psychiatry, 60, 253-264.
143. Morgan, C., Kirkbride, J., Leff, J., Craig, T., Hutchinson, G., McKenzie, K., Morgan, K., Dazzan, P., Doody, G. A., Jones, P., Murray, R., & Fearon, P. (2007). Parental separation, loss and psychosis in different ethnic groups: A case-control study. Psychological Medicine, 37, 495-503.
144. Nielsen, P. R., Laursen, T. M., & Mortensen, P. B. (2011). Association between parental hospital- treated infection and the risk of schizophrenia in adolescence and early adulthood. Schizophrenia Bulletin, 39(1), 230-237. PMID: 22021661.
145. Niitsu, T., Shirayama, Y., Matsuzawa, D., Hasegawa, T., Kanahara, N., Hashimoto, T., Shiraishi, T., Shiina, A., Fukami, G., Fujisaki, M., Watanabe, H., Nakazato, M., Asano, M., Kimura, S., Hashimoto, K., & Iyo, M. (2011). Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Progress in NeuroPsychopharmacology & Biological Psychiatry, 35, 1836-1840.
146. Niu, C., & Yip, H. K. (2011). Neuroprotective signaling mechanisms of telomerase are regulated by brain-derived neurotrophic factor in rat spinal cord motor neurons. Journal of Neuropathology and Experimental Neurology, 70, 634-652.
147. Niu, S., Yabut, O., & D'Arcangelo, G. (2008). The reelin signaling pathway promotes dendritic spine development in hippocampal neurons. The Journal of Neuroscience, 28, 10339-10348.
148. Nouel, D., Burt, M., Zhang, Y., Harvey, L., & Boksa, P. (2012). Prenatal exposure to bacterial endotoxin reduces the number of GAD67- and reelin-immunoreactive neurons in the hippocampus of rat offspring. European Neuropsychopharmacology, 22, 300-307.
149. O'Donnell, P., Lewis, B. L., Weinberger, D. R., & Lipska, B. K. (2002). Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cerebral Cortex, 12, 975-982.
150. Olas, B., Kedzierska, M., & Wachowicz, B. (2008). Comparative studies on homocysteine and its metabolite - Homocysteine thiolactone action in blood platelets in vitro. Platelets, 19, 520-527.
151. Onishi, T., Iwashita, H., Uno, Y., Kunitomo, J., Saitoh, M., Kimura, E., Fujita, H., Uchiyama, N., Kori, M., & Takizawa, M. (2011). A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3- (4-[(S)-methylsulfinyl]phenyl)-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 119, 1330-1340.
152. Pae, C. U., Chiesa, A., Porcelli, S., Han, C., Patkar, A. A., Lee, S. J., Park, M. H., Serretti, A., & De Ronchi, D. (2012). Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology, 65(1), 1-11.
153. Palomino, A., Vallejo-Illarramendi, A., Gonzalez-Pinto, A., Aldama, A., Gonzalez-Gomez, C., Mosquera, F., Gonzalez-Garcia, G., & Matute, C. (2006). Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophrenia Research, 6, 321-322.
154. Park, S. W., Lee, J. G., Kong, B. G., Lee, S. J., Lee, C. H., Kim, J. I., & Kim, Y. H. (2009). Genetic association of BDNF val66met and GSK-3beta-50 T/C polymorphisms with tardive dyskinesia. Psychiatry and Clinical Neuroscience, 63, 433-439.
155. Pascual, M., Perez-Sust, P., & Soriano, E. (2004). The GABAergic septohippocampal pathway in control and reeler mice: Target specificity and termination onto reelin-expressing interneurons. Molecular and Cellular Neuroscience, 25, 679-691.
156. Pedrini, M., Chendo, I., Grande, I., Lobato, M. I., Belmonte-de-Abreu, P. S., Lersch, C., Walz, J., Kauer-Sant'anna, M., Kapczinski, F., & Gama, C. S. (2011). Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia, a positive correlation. Neuroscience Letters, 491, 207-210.
157. Pedrini, M., Massuda, R., Fries, G. R., de Bittencourt Pasquali, M. A., Schnorr, C. E., Moreira, J. C. F., Teixeira, A. L., Lobato, M. I. R., Walz, J. C., Belmonte-de-Abreu, P. S., Kauer- Sant'anna, M., Kapczinski, F., & Gama, C. S. (2012). Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. Journal of Psychiatric Research, 46, 819-824.
158. Perez-Costas, E., Gandy, J. C., Melendez-Ferro, M., Roberts, R. C., & Bijur, G. N. (2010). Light and electron microscopy study of glycogen synthase kinase-3beta in the mouse brain. PloS One, 5, e8911.
159. Pesold, C., Impagnatiello, F., Pisu, M. G., Uzunov, D. P., Costa, E., Guidotti, A., & Caruncho, H. J. (1998). Reelin is preferentially expressed in neurons synthesizing gamma-aminobutyric acid in cortex and hippocampus of adult rats. Proceedings of the National Academy of Sciences of the United States of America, 95, 3221-3226.
160. Pert, L., Ferriter, M., & Saul, C. (2004). Parental loss before the age of 16 years: A comparative study of patients with personality disorder and patients with schizophrenia in a high secure hospital's population. Psychology and Psychotherapy, 77(Pt 3), 403-407.
161. Pisante, A., Bronstein, M., Yakir, B., & Darvasi, A. (2009). A variant in the reelin gene increases the risk of schizophrenia and schizoaffective disorder but not bipolar disorder. Psychiatric Genetics, 19, 212.
162. Pollard, M., Varin, C., Hrupka, B., Pemberton, D. J., Steckler, T., & Shaban, H. (2012). Synaptic transmission changes in fear memory circuits underlie key features of an animal model of schizophrenia. Behavioural Brain Research, 227, 184-193.
163. Rice, D., & Barone, S. (2000). Critical periods of vulnerability for the developing nervous system: Evidence from human and animal models. Environmental Health Perspectives, 108(Suppl. 3), 511-533.
164. Richard, M. D., & Brahm, N. C. (2012). Schizophrenia and the immune system: Pathophysiology, prevention, and treatment. American Journal of Health-System Pharmacy, 69, 757-766.
165. Rizos, E. N., Rontos, I., Laskos, E., Arsenis, G., Michalopoulos, P. G., et al. (2008). Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Progress in NeuroPsychopharmacology & Biological Psychiatry, 32, 1308-1311.
166. Rizos, E. N., Papadopoulou, A., Laskos, E., Michalopoulos, P. G., Kastania, D., Vasilopoulos, D., Katsafouros, K., & Lykouras, L. (2010). Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. The World Journal of Biological Psychiatry, 1, 251-255.
167. Rosenberg, S. D., Lu, W., Mueser, K. T., Jankowski, M. K., & Cournos, F. (2007). Correlates of adverse childhood events among adults with schizophrenia spectrum disorders. Psychiatric Services, 58, 245-253.
168. Sachdev, P. S., Valenzuela, M., Wang, X. L., Looi, J. C., & Brodaty, H. (2002). Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology, 58, 1539-1541.
169. Sanderson, T. M., Cotel, M. C., O'Neill, M. J., Tricklebank, M. D., Collingridge, G. L., & Sher, E. (2012). Alterations in hippocampal excitability, synaptic transmission and synaptic plasticity in a neurodevelopmental model of schizophrenia. Neuropharmacology, 62, 1349-1358.
170. Sawa, A., & Snyder, S. H. (2002). Schizophrenia: Diverse approaches to a complex disease. Science, 296, 692-695.
171. Schutte, D. L., Reed, D., Decrane, S., & Ersig, A. L. (2011). Saitohin and APOE polymorphisms influence cognition and function in persons with advanced alzheimer disease. Dementia and Geriatric Cognitive Disorders, 32, 94-102.
172. Shinohara, M., Ybanez, M. D., Win, S., Than, T. A., Jain, S., Gaarde, W. A., Han, D., & Kaplowitz, N. (2010). Silencing glycogen synthase kinase-3beta inhibits acetaminophen hep- atotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. The Journal of Biological Chemistry, 285, 8244-8255.
173. Singh, K. K., De Rienzo, G., Drane, L., Mao, Y., Flood, Z., Madison, J., Ferreira, M., Bergen, S., King, C., Sklar, P., Sive, H., & Tsai, L. H. (2011). Common DISC1 polymorphisms disrupt Wnt/GSK3ß signaling and brain development. Neuron, 72, 545-558.
174. Somenarain, L., & Jones, L. B. (2010). A comparative study of MAP2 immunostaining in areas 9 and 17 in schizophrenia and huntington chorea. Journal of Psychiatric Research, 44, 694-699.
175. Song, H., Ueno, S., Numata, S., Iga, J., Shibuya-Tayoshi, S., Nakataki, M., Tayoshi, S., Yamauchi, K., Sumitani, S., Tomotake, T., Tada, T., Tanahashi, T., Itakura, M., & Ohmori, T. (2007). Association between PNPO and schizophrenia in the Japanese population. Schizophrenia Research, 97, 264-270.
176. Steiner, J., Bogerts, B., Schroeter, M. L., & Bernstein, H. G. (2011). S100B Protein in neurodegenerative disorders. Clinical Chemistry and Laboratory Medicine, 49, 409-424.
177. Stone, J. M., Day, F., Tsagaraki, H., Valli, M. L. M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., McGuire, P. K., & OASIS. (2009). Glutamate dysfunction in people with prodromal symptoms of psychosis: Relationship to grey matter volume. Biological Psychiatry, 66, 533-539.
178. Sullivan, E. M., & O'Donnell, P. (2012). Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophrenia Bulletin, 38, 373-376.
179. Sullivan, P. F., Kendler, K. S., & Neale, M. C. (2003). Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Archives of General Psychiatry, 60, 1187-1192.
180. Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., & Alberini, C. M. (2011). Astrocyte-neuron lactate transport is required for long-term memory formation. Cell, 144, 810-823.
181. Suzuki, K., Nakamura, K., Iwata, Y., Sekine, Y., Kawai, M., Sugihara, G., Tsuchiya, K. J., Suda, S., Matsuzaki, H., Takei, N., Hashimoto, K., & Mori, N. (2008). Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients. Schizophrenia Research, 98, 148-156.
182. Swanson, R. A. (1992). Physiologic coupling of glial glycogen metabolism to neuronal activity in brain. Canadian Journal of Physiology and Pharmacology, 70(Suppl), S138-S144.
183. Tan, Y. L., Zhou, D. F., & Zhang, X. Y. (2005). Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements. Schizophrenia Research, 74, 263-270.
184. 1H-MRS). Schizophrenia Research, 108, 69-77.
185. Tedia, Y., Shibre, T., Ali, O., Tadele, G., Woldeamanuel, Y., Asrat, D., Aseffa, A., Mihret, W., Abebe, M., Alem, A., Medhin, G., & Habte, A. (2011). Serum antibodies to toxoplasma gondii and herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: A case- control study. Ethiopian Medical Journal, 49, 211-220.
186. Theberge, J., Williamson, K. E., Aoyama, N., Drost, D. J., Manchanda, R., Malla, A. K., Northcott, S., Menon, R. S., Neufeld, R. W., Rajakumar, N., Pavlosky, W., Densmore, M., Schaefer, B., & Williamson, P. C. (2007). Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. The British Journal of Psychiatry, 191, 325-334.
187. Thoma, R. J., Monnig, M., Hanlon, F. M., Miller, G. A., Petropoulos, H., Mayer, A. R., Yeo, R., Euler, M., Lysne, P., Moses, S. N., & Cahive, J. M. (2009). Hippocampus volume and episodic memory in schizophrenia. Journal of the International Neuropsychological Society, 15, 182-195.
188. Tibbo, P., Hanstock, C., Valiakalayil, A., & Allen, P. (2004). 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. The American Journal of Psychiatry, 161, 1116-1118.
189. Tosic, M., Ott, J., Barral, S., Bovet, P., Deppen, P., Gheorghita, F., Matthey, M. L., Parnas, J., Preisig, M., Saraga, M., Solida, A., Timm, S., Wang, A. G., Werge, T., Cuenod, M., & Do, K. Q. (2006). Schizophrenia and oxidative stress: Glutamate cysteine ligase modifier as a susceptibility gene. The American Journal of Human Genetics, 79, 586-592.
190. Traver, S., Marien, M., Martin, E., Hirsch, E. C., & Michel, P. P. (2006). The phenotypic differentiation of locus coeruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotrophin releasing factor through the activation of a cAMP-dependent signaling pathway. Molecular Pharmacology, 70, 30-40.
191. Tseng, K. Y., Lewis, B. L., Lipska, B. K., & O'Donnell, P. (2007). Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. Biological Psychiatry, 62, 730-738.
192. Tseng, K. Y., Chambers, R. A., & Lipska, B. K. (2009). The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behavioural Brain Research, 204, 295-305.
193. Tueting, P., Doueiri, M. S., Guidotti, A., Davis, J. M., & Costa, E. (2006). Reelin down-regulation in mice and psychosis endophenotypes. Neuroscience and Biobehavioral Reviews, 30, 1065-1077.
194. Turetsky, B. I., Moberg, P. J., Roalf, D. R., Arnold, S. E., & Gur, R. E. (2003). Decrements in volume of anterior ventromedial temporal lobe and olfactory dysfunction in schizophrenia. Archives of General Psychiatry, 60, 1193-1200.
195. Valenti, O., Cifalli, P., Gill, K. M., & Grace, A. A. (2011). Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. The Journal of Neuroscience, 31, 12330-12338.
196. Ventruti, A., Kazdoba, T. M., Niu, S., & D'Arcangelo, G. (2011). Reelin deficiency cause specific defects in the molecular composition of the synapses in the adult brain. Neuroscience, 189, 32-42.
197. Virgili, M., Vandi, M., & Contestabile, A. (1997). Ischemic and excitotoxic damage to brain slices from normal and microencephalic rats. Neuroscience Letters, 233, 53-57.
198. Walton, N. M., Shin, R., Tajinda, K., Heusner, C. L., Kogan, J. H., Miyake, S., Chen, Q., Tamura, K., & Matsumoto, M. (2012). Adult neurogenesis transiently generates oxidative stress. PloS One, 7(4), e35264.
199. Wang, Y., Gao, L., Conrad, C. G., & Andreadis, A. (2011). Saitohin, which is nested within the tau gene, interacts with tau and Abl and its human-specific allele influences Abl phosphorylation. Journal of Cellular Biochemistry, 112, 3482-3488.
200. Welch, K. A., McIntosh, A. M., Job, D. E., Whalley, H. C., Moorhead, T. W., Hall, J., Owens, D. G., Lawrie, S. M., & Johnstone, E. C. (2011). The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophrenia Bulletin, 37, 1066-1076.
201. Wender, R., Brown, A. M., Fern, R., Swanson, R. A., Farrell, K., & Ransom, B. R. (2000). Astrocytic glycogen influences axon function and survival during glucose deprivation in central white matter. The Journal of Neuroscience, 20, 6804-6810.
202. Wexler, B. E., Zhu, H., Bell, M. D., Nicholls, S. S., Fulbright, R. K., Gore, J. C., Colibazzi, T., Amat, J., Bansal, R., & Peterson, B. S. (2009). Neuropsychological near normality and brain structure abnormality in schizophrenia. The American Journal of Psychiatry, 166, 189-195.
203. Wexler, E. M., & Geschwind, D. H. (2011). DISC1: A schizophrenia gene with multiple personalities. Neuron, 72, 501-503.
204. Yang, Y. Q., Sun, S., Yu, Y. Q., Li, W. J., Zhang, X., & Xiu, M. H. (2011). Decreased serum brain- derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neuroscience Letters, 502, 37-40.
205. Yao, J. K., Reddy, R., Meelhinny, L. G., & Van Kammen, D. P. (1998). Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophrenia Research, 55, 33-34.
206. Yao, J. K., Reddy, R., Meelhinny, L. G., & Van Kammen, D. P. (2001). Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs, 15, 287-310.
207. Yoshimura, R., Hori, H., Sugita, N., Ueda, N., & Kakihara, S. (2007). Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 31, 1072-1077.
208. Yoshimura, R., Ueda, N., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., et al. (2010). Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. The World Journal of Biological Psychiatry, 11, 256-261.
209. Yu, Q., Plis, S. M., Erhardt, E. B., Allen, E. A., Sui, J., Kiehl, K. A., Pearlson, G., & Calhoun, V. D. (2011). Modular organization of functional network connectivity in healthy controls and patients with schizophrenia during the resting state. Frontiers in Systems Neuroscience, 5, 103.
210. Zai, C. C., Tiwari, A. K., De Luca, V., Muller, D. J., Bulgin, N., Hwang, R., Zai, G. C., King, N., Voineskos, A. N., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Remington, G., & Kennedy, J. L. (2009). Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. European Neuropsychopharmacology, 19, 317-328.
211. Zaidel, D. W., Esiri, M. M., & Harrison, P. J. (1997). Size, shape and orientation of neurons in the left and right hippocampus: Investigation of normal asymmetries and alterations in schizophrenia. The American Journal of Psychiatry, 154, 812-818.
212. Zhang, X. Y., Xiu, M. H., da Chen, C., Zhu, F. Y., Wu, G. Y., Haile, C. N., Lu, L., Kosten, T. A., & Kosten, T. R. (2010). Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements. Journal of Psychiatric Research, 44, 429-433.
213. Zhang, X. Y., Chen, D. C., Xiu, M. H., Hui, L., Liu, H., Luo, X., Zuo, L., Zhang, H., Kosten, T. A., & Kosten, T. R. (2012a). Association of functional dopamine-beta-hydroxylase (DBH) 19 bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers. Schizophrenia Research, 141(1), 48-53. PMID: 22871345.
214. Zhang, X. Y., Liang, J., Chen, D. C., Xiu, M. H., De Yang, F., Kosten, T. A., & Kosten, T. R. (2012b). Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berlin), 222(2), 277-284. PMID: 22274000.